1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A68F2356FD786AB965258384001C1BDF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-competitive-intelligence-landscape-assessment-activities-investment-staffing?opendocument
18
19opendocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Competitive and Business Intelligence Resource/ Budget

Competitive Intelligence Landscape Assessment: Activities, Investment and Staffing

ID: 5543


Features:

12 Info Graphics

14 Data Graphics

160+ Metrics


Pages/Slides: 34


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Competitive Intelligence Landscape Assessment: Activities, Investment and Staffing”

STUDY OVERVIEW

Competitive Intelligence groups help organizations meet the ever-growing challenges in the biopharmaceutical industry by providing actionable insights that help set the strategic and tactical direction for the company. However, it is important to maintain a balance between developing competent functional capabilities and managing limited resources.

Best Practices, LLC conducted this landscape assessment using a meta-analysis approach to identify evolutionary insights for Competitive Intelligence activities, staffing and investment in the biopharmaceutical industry. Insights in this research have been distilled from 10 of Best Practices, LLC’s existing benchmarking studies.

KEY TOPICS

  • Competitive Intelligence activities across product lifecycle
  • Competitive Intelligence investment levels for global organizations
  • Competitive Intelligence staffing levels & skill sets in high-performing companies
  • Roles & scope of Competitive Intelligence teams
  • Competitive Intelligence as enabler of leadership and best decision making
  • Case studies to show management how best-in-class Competitive Intelligence functions contribute and add value

KEY METRICS
  • Rank the listed Competitive Intelligence activities in order of importance for optimal performance of Competitive Intelligence function
  • Allocation of Competitive Intelligence budget across different categories
  • Competitive Intelligence budget per FTE / $1B in revenue
  • Competitive Intelligence budget as a percentage of revenue
  • Number of FTEs per $1B in revenue
  • Average salary per Competitive Intelligence FTE
  • Which five of the listed employee competencies are most important for delivering maximum value Competitive Intelligence performance?
  • Select top three most critical training topics for development of a strong Competitive Intelligence staff
  • What is the job level of the person to whom the leader (direct manager) of Competitive Intelligence function directly reports?
  • Who are the key stakeholders for your Competitive Intelligence function?
  • What is the functional area of the person to whom the leader (direct manager) of your Competitive Intelligence function directly reports?
  • How many levels of management are there between the Competitive Intelligence head and the company's CEO?
  • What is the title of the highest-level member of the Competitive Intelligence organization?

SAMPLE KEY FINDINGS
  • Most Important Competitive Intelligence Activities: Tracking of competitor products and clinical trials are the highest ranked general Competitive Intelligence activities.
  • Competitive Intelligence Budget Allocation: Labor (29%) and vendor costs (22%) consume about half of the Competitive Intelligence budget.
  • Competitive Intelligence FTE Levels: Competitive Intelligence FTE levels range from 0.23 To 3.5 FTEs per $1B in revenue supported, reflecting resource & portfolio differences.

METHODOLOGY

Best Practices, LLC captured data from ten of its benchmarking studies to conduct a Competitive Intelligence Landscape Assessment for the biopharmaceutical sector.


Industries Profiled:
Medical Device; Pharmaceutical; Health Care; Diagnostic; Manufacturing; Biotech; Biopharmaceutical; Technology; Communications; Consumer Products; Banking; Financial Services; Insurance; Research; Marketing; Chemical; High Tech; Consulting; Service; Electronics; Internet; Distribution; Computer Software; Energy; Clinical Research; Laboratories; Computers; Utilities; Telecommunications; Engineering; Shipping; Professional Services; Logistics; Science


Companies Profiled:
3M Pharmaceuticals; Abbott; Abbott Nutrition; Abbott Laboratories; AbbVie; actavis; Aditya Birla Group; Adocia; Alcon; Alcon Laboratories; Alembic; Alkermes; Allergan; Alnylam Pharmaceuticals; Amgen; Amylin; Anoto; ApotheCom; ARIAD; Array BioPharma; Astellas; AstraZeneca; B.Braun; Bausch & Lomb; Baxter Healthcare; Baxter International; Bayer Healthcare; Bayer; Biocon; BioCryst Pharmaceuticals; Biogen; Biogen Idec; Biological E. Limited; BioMarin; Biovail; Bioventus; Boehringer Ingelheim; Bristol-Myers Squibb; Cadila Pharmaceuticals; Centocor; Inc.; Central Bank of India; Citibank; Colorcon; ConjuChem Biotechnologies; Covance; Covidien; CSL Behring; Cubist Pharmaceuticals; Daiichi Sankyo; Datamatics Financial Services; Dendreon Corporation; Dentsply International; Diners Club International; doTerra; Dr Reddy's Laboratories; Eisai; Eli Lilly and Company; EMD Serono; Emergent BioSolutions; Endo Pharmaceuticals; Essilor International S.A.; Ethicon Endo-Surgery Inc.; Ethicon; Johnson & Johnson; Ethos Health Communications; Farma Health; Ferring Pharmaceuticals; Genentech; GlaxoSmithKline ; Gilead Sciences; Glenmark; Grifols; Human Genome Sciences; IBM; Immunex; IMS Health; Indegene Lifesystems; Infosys; Inspire Pharmaceuticals; Intel; Intermountain Healthcare; Ipsen; Ironwood; Janssen; Jazz Pharmaceuticals; King Pharmaceuticals; Kodak; Lac Mac; Lilly; Lonza Inc.; Mallinckrodt; McKesson; MedImmune; Medtronic; Medrad; Merck; Merck Serono; MyDataBall; Novartis; Nova Nordisk; Oracle; Orion Pharmaceuticals; PDL; PDL BioPharma; Pfizer; Pharma Consulting; Phillips; Procter & Gamble Pharma; Progress Energy; ProStrakan; Purdue Pharma; Quintiles; Ranbaxy; Roche; Rxperts; Salt Creek Biosciences; Sanofi; Sanofi Pasteur; Sanofi-Aventis; Santen; SAS; Sequor; Shire; Stiefel; Sunovion; Syntel; Takeda Pharmaceuticals; Tata Technologies; Teleflex; Tesaro; Teva Pharmaceutical Industries Ltd; Theratechnologies; Torrent Pharmaceuticals Ltd.; Transform Strategy Partners; UCB Pharma; UPS; Upsher-Smith; Vertex Pharmaceuticals; Vifor Pharma; Vivus; VMware; Waters; Waters Corporation; Women's Choice Pharmaceuticals; Wyeth Nutrition/Nestle; Xanodyne Pharmaceuticals; Zydus

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.